Poxel SA

Explore Poxel’s journey from Japan’s Imeglimin approval to NASH trials, uncovering the company’s high‑risk biotech challenges and partnership strategy for metabolic disease breakthroughs.

Explore Poxel S.A.’s latest biotech strides—imeglimin for type‑2 diabetes, NASH trials, and partnership strategies—while assessing its volatile market performance and uncertain outlook.

Discover how Poxel S.A. is pioneering mitochondrial‑based therapies for type 2 diabetes and NASH, with its flagship drug Imeglimin now approved in Japan.

Poxel SA is a pioneering biopharmaceutical company that is revolutionizing the treatment of Type 2 diabetes with its innovative drugs, including Imeglimin, a promising candidate in clinical phase 2 studies.